Annals of Oncology Advance Access published online on March 17, 2005
Annals of Oncology, doi:10.1093/annonc/mdi152
1 Departments of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey
* To whom correspondence should be addressed. Background: The level of serum cardiac troponin-T (cTnT) increases with myocardial damage. We sought to assess whether cTnT level could be a useful marker for the early detection of anthracycline cardiotoxicity. Patients and methods: Forty-one patients who had been scheduled to receive anthracycline-containing combination chemotherapy were included in the study. Serum cTnT levels were measured before (baseline) and after the first cycle of chemotherapy, and again, after the last cycle of chemotherapy. In all patients, the left ventricular ejection fraction (LVEF), fractional shortening (FS), early peak flow/atrial flow velocity (E/A) ratio, and the isovolemic relaxation time (IRT) were measured echocardiographically, both before and after the completion of chemotherapy. Results: LVEF and FS did not change in any patients. In 21 patients (49%), the E/A ratio decreased after therapy as compared to the pre-treatment values. The decrease in E/A ratio was more prominent in patients who were older than the mean age of our study group, which was 44 years. The post-treatment IRT was prolonged compared with the pretreatment IRT (94.0 ± 2.0 versus 85.6 ± 10.5 ms, respectively). cTnT levels after completion of therapy were elevated in 14 (34%) patients, and exceeded the upper limit of the normal range (>0.1 ng/ml) in only one patient. cTnT levels measured after completion of therapy were significantly higher, compared with those measured at baseline and after the first cycle of therapy. In the younger age group ( Conclusion: Increased serum cTnT level can be detected in the early stages of anthracycline therapy and it is associated with diastolic dysfunction of the left ventricle. Therefore, serum cTnT level could be a useful measure for early detection of anthracycline-induced cardiotoxicity.
Received September 7, 2004
Revised December 14, 2004
Accepted December 15, 2004
Original article
cTnT can be a useful marker for early detection of anthracycline cardiotoxicity
2 Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey
S. Kilickap, E-mail: skilickap{at}yahoo.com
Abstract 
44 years old), there was a two-fold decrease in the E/A ratio in those patients whose cTnT levels increased during the therapy, when compared with those whose cTnT levels did not change (21% versus 43%, respectively).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. J. Barrett-Lee, J. M. Dixon, C. Farrell, A. Jones, R. Leonard, N. Murray, C. Palmieri, C. J. Plummer, A. Stanley, and M. W. Verrill Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk Ann. Onc., May 1, 2009; 20(5): 816 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mantovani, C. Madeddu, C. Cadeddu, M. Dessi, A. Piras, E. Massa, R. Serpe, G. Antoni, and G. Mercuro Persistence, Up to 18 Months of Follow-Up, of Epirubicin-Induced Myocardial Dysfunction Detected Early by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers Oncologist, December 1, 2008; 13(12): 1296 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Horacek, M. Tichy, R. Pudil, and L. Jebavy Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity Ann. Onc., September 1, 2008; 19(9): 1656 - 1657. [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Armenian and S. Bhatia Cardiovascular disease after hematopoietic cell transplantation - lessons learned Haematologica, August 1, 2008; 93(8): 1132 - 1136. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Perik, B. Rikhof, F. A. de Jong, J. Verweij, J. A. Gietema, and W. T. A. van der Graaf Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity Ann. Onc., February 1, 2008; 19(2): 359 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 NACB WRITING GROUP MEMBERS, A. H.B. Wu, A. S. Jaffe, F. S. Apple, R. L. Jesse, G. L. Francis, D. A. Morrow, L. K. Newby, J. Ravkilde, W.H. W. Tang, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure Clin. Chem., December 1, 2007; 53(12): 2086 - 2096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mercuro, C. Cadeddu, A. Piras, M. Dessi, C. Madeddu, M. Deidda, R. Serpe, E. Massa, and G. Mantovani Early Epirubicin-Induced Myocardial Dysfunction Revealed by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers Oncologist, September 1, 2007; 12(9): 1124 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cardinale, G. Lamantia, and C. M. Cipolla Troponin I and Cardiovascular Risk Stratification in Patients With Testicular Cancer J. Clin. Oncol., July 20, 2006; 24(21): 3508 - 3508. [Full Text] [PDF]
|
|
|
|
|
|
D. Cardinale, M. Civelli, and C. M. Cipolla Troponins in prediction of cardiotoxic effects Ann. Onc., January 1, 2006; 17(1): 173 - 173. [Full Text] [PDF]
|
|
|
|
|
|
S. Kilickap, I. Barista, and K. Aytemir Reply to "Troponins in prediction of cardiotoxic effects", by D. Cardinale et al. Ann. Onc., January 1, 2006; 17(1): 173 - 174. [Full Text] [PDF]
|
|
E-letters:
Read all E-letters
- “ Troponins in prediction of cardiotoxic effects.”
- Daniela Cardinale, et al.
- Annals of Oncology, 3 May 2005 [Full text]
- Response to “Troponins in prediction of cardiotoxic effects.”
- Saadettin Kilickap, et al.
- Annals of Oncology, 13 Jun 2005 [Full text]